Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Lifecycle Trial: Dapagliflozin in Severe Chronic Kidney Disease
NCT05374291Phase 3Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2022
- Primary completion
- Jul 2027
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD), heart failure (HF) and kidney failure (ESRD) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: All-cause mortality, kidney failure, and hospitalization for heart failure at 48 months. Started Nov 2022; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)heart failure (HF)kidney failure (ESRD)
Beyond the preview
Go deeper on NCT05374291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05374291.